Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 13/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4889367 | 0.83 | EGLN1 (0.40) | DRD2HDAC1HDAC2HDAC3NR4A2 | |
| SCHEMBL21389397 | 0.78 | ALDH1A1 (0.47) | DRD2 | |
| SCHEMBL4897978 | 0.77 | DRD2 (0.45) | DRD2 | |
| SCHEMBL3865465 | 0.74 | LTA4H (0.40) | HDAC2NR4A2 | |
| SCHEMBL30887808 | 0.74 | HDAC1 (0.54) | HDAC1HDAC2MEN1KMT2A | |
| SCHEMBL15765305 | 0.74 | DRD2 (0.52) | DRD2 | |
| SCHEMBL3859168 | 0.72 | LTA4H (0.47) | HDAC2NR4A2 | |
| SCHEMBL4894394 | 0.71 | KDM4E (0.50) | HDAC2 | |
| SCHEMBL27194836 | 0.70 | DHFR (0.40) | HDAC1HDAC2HDAC3NR4A2 | |
| SCHEMBL26208949 | 0.70 | PRMT5 (0.49) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314087-B2 | Nitrogen-containing heterocyclyl ketones and methods of use | AMGEN INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314087-B2 | Nitrogen-containing heterocyclyl ketones and methods of use | AMGEN INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20080280917-A1 | Nitrogen-Containing heterocyclyl ketones and methods of use | AMGEN INC. (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080280917-A1 | Nitrogen-Containing heterocyclyl ketones and methods of use | AMGEN INC. (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080280917-A1 | Nitrogen-Containing heterocyclyl ketones and methods of use | AMGEN INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008103277-A2 | NITROGEN-CONTAINING HETEROCYCLYL KETONES AND THEIR USE AS C-MET INHIBITORS | AMGEN INC. (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280917-A1 | Nitrogen-Containing heterocyclyl ketones and methods of use | HGF, HGFAC, MET | DRD2 4351/4885HDAC1 1251/4885HDAC2 2491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.